[125I]-omega conotoxin binding to human frontal cortex from normal, Alzheimer's and non-Alzheimer's dementia patients. 1990

R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
Department of Pharmacology, Oral Roberts University School of Medicine, Tulsa, OK.

We studied the binding of the calcium antagonist neurotoxin [125I]-omega conotoxin (GVIA) in age-matched human brains from normal, Alzheimer's disease and non-Alzheimer's dementia patients. Crude preparations of plasmalemmal membranes from frontal cortex were utilized. Saturation isotherms were subjected to Scatchard analysis to determine maximal binding capacity (Bmax) and binding affinity (Kd). In all brain samples tested, [125I]-GVIA binding was homogenous to a single class of high affinity binding sites. Scatchard analysis of saturation isotherms gave the following estimates for normal brains (mean +/- S.D., n = 7): Bmax = .630 +/- .200 pmol/mg and Kd = .177 +/- .054 nM. No significant change was observed in the Kd or Bmax estimates for [125I]-omega conotoxin binding in Alzheimer's disease or non-Alzheimer's dementia brains when compared to normal brains. Although these findings do not rule out the existence of localized changes in calcium channel receptor binding in the frontal cortex of Alzheimer's disease patients, the results do suggest that the neuronal voltage sensitive calcium channel may be unaltered in Alzheimer's disease.

UI MeSH Term Description Entries
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015220 Calcium Channels Voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorized as L-, T-, N-, P-, Q-, and R-types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins. The L- and T-types are present throughout the cardiovascular and central nervous systems and the N-, P-, Q-, & R-types are located in neuronal tissue. Ion Channels, Calcium,Receptors, Calcium Channel Blocker,Voltage-Dependent Calcium Channel,Calcium Channel,Calcium Channel Antagonist Receptor,Calcium Channel Antagonist Receptors,Calcium Channel Blocker Receptor,Calcium Channel Blocker Receptors,Ion Channel, Calcium,Receptors, Calcium Channel Antagonist,VDCC,Voltage-Dependent Calcium Channels,Calcium Channel, Voltage-Dependent,Calcium Channels, Voltage-Dependent,Calcium Ion Channel,Calcium Ion Channels,Channel, Voltage-Dependent Calcium,Channels, Voltage-Dependent Calcium,Voltage Dependent Calcium Channel,Voltage Dependent Calcium Channels
D020866 omega-Conotoxin GVIA A neurotoxic peptide, which is a cleavage product (VIa) of the omega-Conotoxin precursor protein contained in venom from the marine snail, CONUS geographus. It is an antagonist of CALCIUM CHANNELS, N-TYPE. Conus geographus Toxin,Conus geographus Toxin GVIA,omega-CgTX,omega-CgTX GVIA,omega-Conus geographus toxin,GVIA, omega-CgTX,GVIA, omega-Conotoxin,Toxin, Conus geographus,geographus Toxin, Conus,geographus toxin, omega-Conus,omega CgTX,omega CgTX GVIA,omega Conotoxin GVIA,omega Conus geographus toxin,toxin, omega-Conus geographus

Related Publications

R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
June 1992, Brain research,
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
September 1993, Neuroreport,
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
January 1995, Biochimica et biophysica acta,
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
October 1993, Neuroscience letters,
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
January 2006, Methods in molecular biology (Clifton, N.J.),
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
January 1999, Methods in molecular biology (Clifton, N.J.),
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
November 1987, Naunyn-Schmiedeberg's archives of pharmacology,
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
November 1993, Neurochemical research,
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
March 2000, Neurochemical research,
R A Colvin, and R A Allen, and R G Williams, and D T Eagle, and J A Oibo, and G D Miner
July 1989, Journal of neurochemistry,
Copied contents to your clipboard!